GEN-MKT-18-7897-A
Jul 14, 2025 | Blogs, Environmental / Industrial, Food and Beverage, Industrial, SCIEX OS software | 0 comments
Read time: 3 minutes
As PFAS regulations tighten globally, laboratory managers are navigating a complex economic landscape. Whether operating in a commercial or non- commercial setting, the pressure to deliver accurate, defensible, and timely PFAS data is mounting. At SCIEX we understand that the right technology can turn this regulatory challenge into a strategic opportunity.
What lab managers need to know about commercial vs. non- commercial models
As a lab manager, understanding the operational dynamics of different lab types is key to making strategic decisions, especially when it comes to PFAS testing.
Commercial testing
If you are managing a commercial lab your focus is on delivering fast, accurate, and defensible PFAS results while maintaining profitability. This means investing in high-throughput technologies, optimizing workflows, and training your team to meet tight turnaround times and evolving regulatory demands. Efficiency and scalability are your competitive edge.
Non- commercial labs
In academic, government, or public research labs, this mission is different, but no less demanding. Your lab plays a critical role in advancing PFAS science, supporting public health and informing policy. The emphasis is on generating high-quality peer reviewed data that can withstand scientific scrutiny. Timelines still matter, but so does depth and reproducibility.
Why it matters?
Regardless of your lab’s model the expectations are the same: precision, reliability and adaptability. Investing in mass spectrometry- and building a skilled, well supported team are essential to stay ahead in a complex fast-moving world of PFAS testing.
SCIEX mass spectrometry platforms are engineered for labs that need to balance cost-efficiency, regulatory compliance, and analytical excellence. Here’s how SCIEX supports both commercial and non-commercial labs:
For commercial labs, this means faster ROI and greater client satisfaction. For non-commercial labs, it means scientific credibility and methodological flexibility.
PFAS science is evolving rapidly. New compounds, new matrices and new regulations. Labs that invest in flexible, scalable platforms are best equipped to adapt.
SCIEX offers:
As a lab manager, every hour of downtime impacts your throughput, turnaround times, and bottom line. With PFAS testing under increasing regulatory pressure, system reliability isn’t option, it is essential!
Here’s how SCIEX service and support can help you stay productive and profitable:
Regularly serviced systems perform better- delivering more results consistently
SCIEX-trained engineers and specialists can quickly resolve issues, reducing costly delays
Whether you are running our latest Zeno TOF 8600 system or one of our nominal mass systems, our support is customized to your instrument and workflows.
Maximize your ROI with longer instrument life, fewer disruptions, and consistently high data quality
The economics of PFAS testing demand strategic thinking. Laboratory managers must balance cost, compliance, and capacity while preparing for a dynamic regulatory future. SCIEX mass spectrometry platforms offer the precision, productivity and partnership needed to turn PFAS testing into a sustainable opportunity.
Explore how SCIEX can help you lead in PFAS analysis
Discover more >
*This content does not constitute legal advice. You should consult counsel to assure your procedures comply with applicable law and that it meets your needs.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network